Kerry David Fisher
Direktor/Vorstandsmitglied bei The Native Antigen Co. Ltd.
Profil
Kerry David Fisher is the founder of Hybrid BioSystems Ltd., which was founded in 2002.
He held the title of Executive Director & Chief Scientific Officer from 2009 to 2010.
Currently, he is a Non-Executive Director at The Native Antigen Co. Ltd.
since 2010.
Dr. Fisher's former job was as Chief Scientific Officer at Akamis Bio Ltd.
Dr. Fisher's education history includes an undergraduate degree from the University of Aberdeen and a doctorate degree from the University of Birmingham, which was conferred in 2001.
Aktive Positionen von Kerry David Fisher
Unternehmen | Position | Beginn |
---|---|---|
The Native Antigen Co. Ltd.
The Native Antigen Co. Ltd. Miscellaneous Commercial ServicesCommercial Services The Native Antigen Co. Ltd. develops viral vectors technologies. Its products include bacterial antigens, protozoal, and viral antigens. The company was founded by Nick Roesen and Andrew Maxwell in 2010 and is headquartered in Oxford, the United Kingdom. | Direktor/Vorstandsmitglied | 01.09.2010 |
Ehemalige bekannte Positionen von Kerry David Fisher
Unternehmen | Position | Ende |
---|---|---|
Akamis Bio Ltd.
Akamis Bio Ltd. BiotechnologyHealth Technology Akamis Bio Ltd. operates as a biotechnology company which develops novel therapeutics that addresses cancer and other clinically unmet diseases. Its products include Enadenotucirev, Espindolol and AbEnAd. The firm also develops treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines. The company was founded by Andrew Justin Stewart Coats and Stefan D. Anker on November 17, 2006 and is headquartered in Abingdon, the United Kingdom. | Technik-/Wissenschafts-/F&E-Leiter | 16.09.2016 |
Hybrid BioSystems Ltd.
Hybrid BioSystems Ltd. Miscellaneous Commercial ServicesCommercial Services Hybrid is an Oxford Biotechnology Company focused on revolutionizing viral vaccines with its patented vaccine delivery technologies. Hybrid has an established and well equipped laboratory located at Cherwell Innovation Centre in Oxford shire, which houses both its corporate research facility and contract research services. Using a mixed product and platform business model it is developing its in-house lead products towards phase I/II proof of concept clinical trials as well as furthering its partnerships with leading pharmaceutical and biotechnology companies. Hybrid's experienced scientific and management team has reached this late stage of development through a highly efficient use of grant funding and revenues, together with minimal seed funding. With its unparalleled expertise in the field of viral steal thing technologies, The firm is also able to offer general and bespoke virology services, including high-quality adenovirus production and purification. Hybrid BioSystems uses iLabber electronic lab books for maximum IP protection and secure data storage. | Gründer | 15.12.2010 |
Ausbildung von Kerry David Fisher
University of Aberdeen | Undergraduate Degree |
University of Birmingham | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 3 |
---|---|
Hybrid BioSystems Ltd.
Hybrid BioSystems Ltd. Miscellaneous Commercial ServicesCommercial Services Hybrid is an Oxford Biotechnology Company focused on revolutionizing viral vaccines with its patented vaccine delivery technologies. Hybrid has an established and well equipped laboratory located at Cherwell Innovation Centre in Oxford shire, which houses both its corporate research facility and contract research services. Using a mixed product and platform business model it is developing its in-house lead products towards phase I/II proof of concept clinical trials as well as furthering its partnerships with leading pharmaceutical and biotechnology companies. Hybrid's experienced scientific and management team has reached this late stage of development through a highly efficient use of grant funding and revenues, together with minimal seed funding. With its unparalleled expertise in the field of viral steal thing technologies, The firm is also able to offer general and bespoke virology services, including high-quality adenovirus production and purification. Hybrid BioSystems uses iLabber electronic lab books for maximum IP protection and secure data storage. | Commercial Services |
Akamis Bio Ltd.
Akamis Bio Ltd. BiotechnologyHealth Technology Akamis Bio Ltd. operates as a biotechnology company which develops novel therapeutics that addresses cancer and other clinically unmet diseases. Its products include Enadenotucirev, Espindolol and AbEnAd. The firm also develops treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines. The company was founded by Andrew Justin Stewart Coats and Stefan D. Anker on November 17, 2006 and is headquartered in Abingdon, the United Kingdom. | Health Technology |
The Native Antigen Co. Ltd.
The Native Antigen Co. Ltd. Miscellaneous Commercial ServicesCommercial Services The Native Antigen Co. Ltd. develops viral vectors technologies. Its products include bacterial antigens, protozoal, and viral antigens. The company was founded by Nick Roesen and Andrew Maxwell in 2010 and is headquartered in Oxford, the United Kingdom. | Commercial Services |